Dendrite Appoints Patrick J. Zenner, Former President and CEO of Hoffmann-La Roche, Inc. to Board of Directors.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--April 23, 2001

Dendrite International, Inc., the leading provider of sales productivity solutions, analytics, data and sales support services for the worldwide pharmaceutical industry (NASDAQ/NMS:DRTE), today announced the appointment of Patrick J. Zenner to its Board of Directors.

Zenner is a 31-year veteran of the pharmaceutical industry and served as President and Chief Executive Officer of Hoffmann-La Roche, Inc. ("Roche") from 1993 to 2000.

Dendrite President and Chief Executive Officer John Bailye said, "I am pleased to welcome Mr. Zenner to our board. Mr. Zenner's in-depth knowledge of the pharmaceutical industry, combined with his leadership and global marketing experience, will prove to be a tremendous asset for Dendrite."

Zenner joined Roche in 1969 as a sales representative, and subsequently held various marketing and business-development posts, including Senior Vice President of Roche's pharmaceutical division from 1988 to 1993, Head of International Pharmaceutical Marketing from 1988 to 1992 and Vice President and General Manager of Roche Laboratories from 1982 to 1988. He was named President and Chief Executive Officer of Roche in 1993.

"Dendrite is an exciting company, participating in a dynamic industry. I look forward to contributing my expertise to the company's future growth," Zenner said.

Mr. Zenner has also been active in pharmaceutical industry, academic and civil affairs. Mr. Zenner is the immediate past Chairman of the HealthCare Institute of New Jersey and a former Director of the Pharmaceutical Research & Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO). He is also on the Board of Trustees of both Creighton University and Fairleigh Dickinson University. In addition, Mr. Zenner is a member of numerous associations, including the American Foundation for Pharmaceutical Education, the Health Care Leadership Council and the National Committee for Quality Health Care.

ABOUT DENDRITE

Dendrite International, Inc. (NASDAQ/NMS:DRTE) designs and supports technology-based knowledge systems that enhance the competitive activities of sales forces of the world's largest pharmaceutical companies. Over one-third of the pharmaceutical sales representatives and their managers in more than 57 countries worldwide rely on Dendrite to provide these services to maximize representative effectiveness in the field. Headquartered in Morristown, New Jersey, Dendrite employs over 1800 people worldwide. For more information, visit the Company's Web site at http://www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan" and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the Company's 10-K, 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements.